Plus Therapeutics (PSTV) said Wednesday it has signed a manufacturing services agreement with SpectronRx to produce Rhenium Obisbemeda, a radiotherapy for central nervous system cancers.
Financial details weren't disclosed.
Under the agreement SpectronRx will use its facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda, the company said.
The partnership aims to strengthen supply chain redundancy for Plus Therapeutics, ensuring it can meet the demands of late-stage clinical trials and future commercial needs, the company said.
Shares of Plus Therapeutics were down 6.6% in recent Wednesday trading.
Price: 1.27, Change: -0.09, Percent Change: -6.62
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。